Shares of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) rocketed 145 percent higher to $265.61 Thursday on top-line 36-week phase II nonalcoholic steatohepatitis (NASH) data for MGL-3196. The drug showed statistically significant benefits in relative reduction of liver fat, the trial's primary endpoint, and NASH resolution, an accepted FDA regulatory endpoint, fueling new interest in the company's bid to conquer the obesity-linked condition for which no medicines are currently approved.